Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Multi-center, Open Label, Single Arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients

NCT01513850 is registered in ClinicalTrials.gov with SK Chemicals Co., Ltd. as lead sponsor.

NCT NCT01513850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01513850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Multi-center, Open Label, Single Arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients
Lead sponsor
SK Chemicals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2010
Completion date
March 31, 2014
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b